Cocrystal Pharma, Inc. (COCP) - Q1 2025 Filing Summary
Business Context and Reporting Period
Cocrystal Pharma, Inc. is a clinical-stage biopharmaceutical company focused on developing broad-spectrum antiviral drug candidates for influenza, norovirus, coronavirus, and hepatitis C. This Form 10-Q covers the quarterly period ended March 31, 2025. The company operates as a single reportable segment and is currently incurring losses while advancing its product pipeline.
Key Financial Metrics
| Metric | Q1 2025 | Q1 2024 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(2,301,000) | $(3,956,000) |
| Net Loss Per Share (Basic/Diluted) | $(0.23) | $(0.39) |
| Operating Expenses | $2,341,000 | $4,158,000 |
| Research & Development (R&D) | $1,360,000 | $2,950,000 |
| General & Administrative (G&A) | $981,000 | $1,208,000 |
| Cash Used in Operating Activities | $(2,939,000) | $(4,503,000) |
| Cash and Restricted Cash (End of Period) | $6,996,000 | $21,917,000 |
| Total Assets | $10,659,000 | $13,456,000 |
| Total Liabilities | $3,355,000 | $3,933,000 |
| Stockholders' Equity | $7,304,000 | $9,523,000 |
Material Changes vs. Prior Period
- Reduced Net Loss: Net loss decreased by approximately $1.66 million (42%) compared to Q1 2024, driven primarily by a significant reduction in operating expenses.
- R&D Expense Decline: R&D expenses dropped by $1.59 million. Management attributes this to reduced salary costs and the conclusion of the Phase 2a clinical trial for the influenza candidate (CC-42344) and the finalization of the Phase 1 trial for the norovirus/coronavirus candidate (CDI-988).
- G&A Expense Decline: G&A expenses decreased by $227,000 due to lower insurance costs and other administrative reductions.
- Interest Income: Interest income fell from $220,000 in Q1 2024 to $37,000 in Q1 2025, reflecting lower cash balances and potentially lower interest rates on cash equivalents.
- Liquidity Position: Cash and restricted cash decreased by approximately $14.9 million year-over-year, though the burn rate (cash used in operations) improved significantly.
Outlook, Risks, and Management Commentary
- Liquidity and Going Concern: The filing explicitly states that the company's current resources are not sufficient to fund operations beyond the next 12 months. The independent auditor has expressed substantial doubt about the company's ability to continue as a going concern. Continued operations depend on securing additional financing.
- Clinical Trial Updates:
- Influenza (CC-42344): The Phase 2a human challenge study enrollment was extended in December 2024 due to unexpectedly low infection rates among participants. Management is discussing protocol amendments to secure sufficient data.
- Norovirus/Coronavirus (CDI-988): Phase 1 multiple-ascending dose (MAD) results reported in January 2025 showed the drug was safe and well-tolerated at 800 mg. A higher dose cohort (1,200 mg) is ongoing, with results expected in the first half of 2025.
- Capital Resources: The company has an At-The-Market (ATM) offering agreement but reported no sales under this agreement during Q1 2025. Future funding will likely require private or public equity offerings, which may be dilutive.
- Risks: Key risks include the inability to raise capital, delays in clinical trials, regulatory hurdles, and the potential for the company to cease operations if funding is not secured.
Investor Verification Checklist
- Cash Runway: Verify the specific timeline for the next capital raise given the "substantial doubt" regarding going concern status.
- Phase 2a Resolution: Monitor updates on the influenza (CC-42344) Phase 2a study to confirm if the enrollment extension resolves the low infectivity issue.
- CDI-988 High-Dose Data: Await the release of the 1,200 mg cohort results expected in H1 2025 to assess the therapeutic window.
- Equity Dilution: Review the status of the proposed 2025 Equity Incentive Plan (approved by the board, pending shareholder vote) and potential future equity issuances.
- Related Party Transactions: Note the lease agreement with a limited liability company controlled by a director (Dr. Phillip Frost) and its impact on operating expenses.